Investors Purchase High Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) was the recipient of unusually large options trading on Monday. Stock traders purchased 42,625 call options on the company. This represents an increase of approximately 52% compared to the typical volume of 27,996 call options.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded up $0.52 during mid-day trading on Monday, hitting $16.81. 7,976,840 shares of the company were exchanged, compared to its average volume of 11,026,337. The business has a 50 day simple moving average of $14.19 and a 200-day simple moving average of $12.20. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.20. The stock has a market capitalization of $18.85 billion, a PE ratio of -41.00, a price-to-earnings-growth ratio of 1.94 and a beta of 1.04. Teva Pharmaceutical Industries has a 1-year low of $7.09 and a 1-year high of $17.13.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group raised their price objective on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a "neutral" rating in a report on Monday, February 5th. Piper Sandler restated an "overweight" rating and issued a $20.00 price objective (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the company an "overweight" rating in a research note on Thursday, May 9th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 10th. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 target price for the company in a research note on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $14.22.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 15,500 shares of the stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $16.80, for a total transaction of $260,400.00. Following the completion of the transaction, the chief accounting officer now owns 17,814 shares in the company, valued at approximately $299,275.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Vikki L. Conway sold 15,219 shares of the firm's stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $16.74, for a total value of $254,766.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Amir Weiss sold 15,500 shares of the firm's stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total value of $260,400.00. Following the completion of the transaction, the chief accounting officer now owns 17,814 shares of the company's stock, valued at approximately $299,275.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 141,900 shares of company stock worth $2,013,861. Corporate insiders own 0.55% of the company's stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds have recently bought and sold shares of TEVA. New Covenant Trust Company N.A. acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $28,000. iA Global Asset Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $1,436,000. California State Teachers Retirement System raised its position in shares of Teva Pharmaceutical Industries by 13.9% in the first quarter. California State Teachers Retirement System now owns 1,374,231 shares of the company's stock valued at $19,390,000 after buying an additional 167,786 shares in the last quarter. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $54,000. Finally, Iron Triangle Partners LP raised its position in shares of Teva Pharmaceutical Industries by 113.1% in the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company's stock valued at $39,083,000 after buying an additional 1,469,864 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.